result announc may op guidanc
basic estim exclud fx impact compani
assumpt guidanc profit growth outlook sabl
growth analyt measur instrument well revis estim
maintain pt buy
result sale yoy op np
sales/profit sixth straight year sales/profit set new record high
third straight year sale amount op
segment analyt measur instrument sale yoy op
basic line guidanc sale op
full-year chromatograph mass spectromet key model sale
growth flat new
liquid chromatographi lc launch sale book expect begin
lc sale weak ahead new product launch mass spectromet
ms ga chromatograph new product introduc sale upbeat lc
slightli weak environment equip sale basic flat company-wid sale
expect declin strong water quality-rel demand china last year
sale held basic even yoy medic equip sale yoy op
aircraft equip sale op industri
equip sale op
guidanc sale op np
guid anoth record high profit dp forecast yoy assum
fx impact sale op exclud fx
guidanc sale op expens project
capital-expenditure invest basic technolog research lab
healthcar center expect depreci guid
higher profit amid continu growth invest segment guid
analyt measur instrument sale op
opm flat yoy guid higher sales/profit medic system aircraft
equip industri equip well op guidanc street
consid fx assumpt continu growth invest believ
guidanc point steadi underli growth
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
shimadzu japan top analyt instrument maker
larg market share japan asia
competit increas high end product
sale grow profit improv
valuat increas due stabl earn growth
profit increas due weaker jpi assumpt
stabl improv analyt instrument busi
valuat increas driven advanc healthcar
 strengthen sharehold return
scenario base upsid would
profit decreas stronger jpi assumpt
sale declin due macro economi profit remain
sluggish due inventori increas
scenario base downsid would
ev/ebitda
expect profit improv progress
beef after-sal servic busi includ via
 individu business/product margin improv
earn valuat could rise progress
appli advanc analyt instrument technolog
medic field
confirm steadi growth chromatograph
potenti increas sharehold return growth-
invest pay
page
pleas see import disclosur inform page report
us sale op
euro sale op
actual
actual
actual
compani assumpt
price base ev/ebitda fair-valu multipl
bloomberg forecast averag peer us analyt instrument firm
discount differ profit
fx swing chang public budget industri nation
page
pleas see import disclosur inform page report
sale total yoy exclud fx op
sale beat guidanc op miss
street sale line op sale declin yoy first time
quarter albeit slightli op declin yoy first time two quarter
fx yoy basi yen weaken
dollar appreci euro yoy fx impact sale zero
op manag fx assumpt
compar manag assumpt yen weaker dollar
euro simpl calcul fx sensit indic roughli
posit sale versu guidanc posit op
chart analyt instrument sale growth exclud fx op chan
gmp improv yoy sale gpm chang significantli yoy
sg expens yoy ratio sale
 expens yoy expens somewhat restrain
actual investment-ori expens yoy
full year
analyt instrument sale yoy exclud fx
onward growth rate exclud fx low-singl digit sale
mainstay chromatographi mass spectrometri equip yoy
exclud fx compar sale growth exclud fx
flat op
yoy amid slight sale increas somewhat higher growth-ori
invest op also rose slightli
medic system sale yoy exclud fx op
sale america fell yoy north america sale snap back
special demand x-ray equip prior year due increas headcount
page
pleas see import disclosur inform page report
bolster oversea sale framework op declin yoy miss guidanc
one reason lower-than-expect company-wid op
aircraft equip sale yoy op yoy
sales/op declin slightli yoy addit lower sale op declin due chang
product mix higher expens relat new busi roll-out result full-year
op miss guidanc
industri machineri sale yoy op
turbomolecular pump vacuum applic drop yoy due
correct spe market vacuum heat treatment furnac sale use make
carbid tool increas plu strong sale hydraul equip use forklift
truck compens weak elsewher overal sale declin slightli yoy
op rose yoy albeit slightli higher after-sal sale increas overhaul demand
along growth instal base facil expans
sale total yoy exclud fx op
sales/profit increas sixth straight year set new record high
fourth straight year exhibit earn stabil sale beat guidanc
op miss guidanc analyt instrument op line
guidanc medic system miss aircraft equip miss
beat corporate/elimin
fx rate yoy basi yen depreci
dollar rose euro yoy fx impact sale
op
page
pleas see import disclosur inform page report
full-yearquarterli eactualco initialjef ejef eactualactualactualactualactualactualactualjef etot north south asia system north south asia hydraul system rate equip industri machineryanalyt measur instrumentsanalyt measur instrument jp
analyt instrument sale yoy exclud fx sale key
chromatograph mass spectromet sale growth
growth slow mainli comparison
larg order china japan lower gener drug demand
india due currenc appreci fund procur difficulti client firm op
yoy amid slightli rise sale growth-ori invest
increas result op rose slightli
medic system sale yoy exclud fx op
japan europ upbeat north american sale declin yoy
comparison special demand x-ray equip prior fiscal year op declin
yoy cost relat headcount addit bolster sale framework us
aviat equip sale yoy op sale
privat sector sale japanes defenc agenc
defenc agenc sale snap back yoy comparison
bulk purchas prior fiscal year busi restructur expens also book
yoy basi op declin slight drop sale
industri machineri sale yoy op
turbomolecular pump sale yoy sale weaken due
correct spe market demand fpd applic china coat
applic thin-film solar cell upbeat pneumat equip sale
reflect strong demand use forklift truck region japan
china europ sale heat treatment furnac
upbeat op sustain yoy growth strong demand pneumat equip heat
treatment furnac after-sal servic revenu higher overhaul after-market
servic busi revenu along growth instal base
new busi domain develop
combin advanc analyt instrument technolog medic system
advanc healthcar sale total
book analyt instrument book medic system sale
increas yoy progress med-term plan weak
manag attribut weaker-than-expect pharmaceut regulatori
bureau approv new analysi method high barrier replac exist
shimadzu start new medium-term busi plan expect
take time gain critic mass advanc healthcar busi specif
still high hurdl acquir regulatori approv caner screen use
mass spectromet earli diagnosi alzheim diseas also expect
expand roll-out japan oversea medic system ground
includ pet scan mammographi system earli screen also process advanc
also possibl photoimmunotherapi applic includ treatment previous
thought possibl advanc healthcar remain strategi drive shimadzu
growth expect effort field ahead
tabl show factor analysi chang profit op increas yoy
exclud fx neg op increas higher sale boost profit
margin improv higher expens
impact within due higher investment-ori cost
investment-ori cost consist depreci
expens system upgrad etc
page
pleas see import disclosur inform page report
tabl shimadzu factor analysi chang profit
 expens yoy slightli guidanc capital-expenditure
guidanc expenditur
 centr complet februari expans medic equip
plant shiman product capac increas complet februari
depreci come guidanc
yoy oper cf pre-tax
incom work capit cf neg yoy
higher corpor incom tax impact invest cf
yoy fix asset acquisit expenditur increas
busi acquisit expenditur purchas capit subsidiari
also shimadzu acquir medic equip sale compani us
dp yoy total dividend payment pay-out ratio
cash deposit total
result brief presid ueda said think share buyback unchang
polici buy back share base sharehold return rate
achiev balanc growth invest
guidanc sale yoy op np
guid higher sales/profit continu prior year
anoth record high profit assum yoy fx
impact sale op exclud fx impact sale yoy op
guid dp yoy pay-out ratio
shimadzu announc medium-term busi plan march target final-year
sale op opm guidanc clear
target medium-term plan base
page
pleas see import disclosur inform page report
actualjef actualop previou util util competitioncost loss current previou fx fx jp
leav estim
medium-term plan also target oversea sale ratio roe
compani disclosur actual oversea sale ratio
roe clear target
guidanc expens yoy capital-expenditure
invest healthcar centr continu invest
test equip construct new research complex keihanna
technolog research laboratori new complex call shimadzu futur
collaboratori aim make advanc use open innov field
advanc analyt artifici intellig ai innov biotechnolog brain-scienc
five sens shimadzu also decid establish base open innov
tokyo area plan establish shimadzu tokyo innov plaza tent near
haneda airport construct schedul complet decemb area
plan upgrad research environ segment address obsolesc
area
depreci investment-ori expens expect increas
around last year
analyt instrument sale total yoy op
medic system sale op guid
higher sales/profit increas sale angiographi system north america
focal area shimadzu
industri machineri sale op expect
continu strong demand pneumat equip vacuum heat treatment
furnac expect turbomolecular pump sale rebound analyt sale
op expect aircraft equip profit rise
restructur improv busi framework carri
leav estim unchang fine tune newli ad
estim op estim yoy
expect macro uncertainti continu shimadzu sharp fluctuat due
major event crisi bar circumst anticip
stabl earn
us/china trade friction pose demand risk shimadzu busi field via impact
macro environ exclud macro aspect see major direct impact
implic shimadzu export littl china us mainli measur
instrument medic system product produc china focus chines
market even fourth round increas tariff product export
china shimadzu directli affect us/china trade friction caus chines
govern temporarili reduc subsidi would expect shimadzu see
relat public sector applic field name
pharmaceut food environment
base believ impact us/china trade friction shimadzu
would rel minor
page
pleas see import disclosur inform page report
price base ev/ebitda round
result fair-valu multipl bloomberg averag rival us
analyt instrument compani discount differ profit
note share price may close shimadzu may close us firm
analyt instrument sale total yoy exclud fx op
exclud fx sale sale
partli reloc order japan howev sale growth onward
low-singl digit
region sale japan sale three key product lc gc
ms post posit growth sale test equip declin mainli
automobil industri north american sale yoy exclud fx
sale upbeat mainli cannabi analysi applic blood concentr
monitor european sale sale pharmaceut
industri contract analysi strong full year sale china
exclud fx sale clinic contract analysi field
strong increas demand due tighten water qualiti monitor
regul environment-rel product declin slightli yoy
level remain high govern demand ratio
ratio around rise howev drop back
public sector ration declin compar normal year due
nation peopl congress lunar new year event sale india
yoy exclud fx sale small/medium-s gener drug maker declin
partli fx sale india tend fluctuat quarterli book
larg order caus sale declin yoy
global sale key product yoy exclud fx ms gc
upbeat lc drop slightli yoy new product announc march actual sale
contribut come sale appar hurt buy
restraint ahead new product launch
measur equip order global around yoy japan
mid-singl digit europ us high-singl digit china
page
pleas see import disclosur inform page report
sale region
page
slightli india remain neg order key product basic flat yoy
sale mc gc increas lc slightli neg yoy partli
restraint ahead launch new product
sale yoy exclud fx op
support upbeat sale profit rose higher expens cost
upgrad oversea sale framework absorb
region sale japan composit sale hard
tester strong full-year deceler name test machin
machineri automobil industri non-destruct test sale key
product declin slightli yoy sale domest pharmaceut industri
rel upbeat start sale declin amid capital-expenditure restraint
drug maker due price revis anoth sourc weak budget
constraint colleges/univers
addit sale benefit larg order sale declin
yoy comparison
japanes govern plan increas science/technology-rel portion
budget univers compon budget could rebound
weak past sever year howev point still concret
sign budget chang direct refer japan
expenditur rise first time three year private-sector
 rose slightli yoy first time two year univers govern
 organ increas slightli first time five year level
five year ago similarli govern scienc technolog budget
rose level basic flat past year
sale america yoy exclud fx north america
sustain high-singl double-digit growth seventh
straight quarter sale key product brisk sale upbeat
environment applic strong healthcar field well reflect steadi
growth use pharmacokinet manag pain manag field progress
made toward test fda approv major develop
legal cannabi qualiti test anoth area drive sale us
order estim yoy us medical/recreational-us
cannabi legal mani state boost demand analysi
equip qualiti manag cultiv process stage well
composit analysi addit legal state level move
relax regul feder level well rais expect market growth
shimadzu line product includ lc ms spectromet need
cannabi analysi shimadzu move develop cannabi analysis-specif applic
consum captur demand field
european sale total european sale rose sharpli
follow temporari slow howev growth resum
upbeat demand ms lc environment university/research institut
food cro field
chines sale growth slow yen
basi remain upbeat saw declin special demand improv gener
drug qualiti manag boost sale environment equip
water qualiti manag post sharp growth sale
drop slightli stain high level sale
china tighten water qualiti restrict support
pleas see import disclosur inform page report
chromatograph mass
growth demand environment equip use on-line measur
organ compound phosphor nitrogen contain plant discharg water
 on-line measur total nitrogen total phosphor total organ
carbon toc field local chines manufactur still larg presenc
leav shimadzu pull regulation-rel demand look ahead water qualiti
monitoring-rel demand expect declin voc volatil organ compound
regul go effect juli support market growth voc
measur instrument see greater competit compar water qualiti
field address market larg environmental-rel demand expect
continu contribut sale
government-rel demand account sale china
basic flat yoy china five-year plan start call project relat
analyt instrument use wide varieti field includ medic food safeti
science/technolog still project remain five-year plan
start plan lag still project contain plan
get underway
sale asian region within sale india
india demand small/medium-s pharma compani
continu declin partli currenc depreci demand
strong southeast asia sale gener drug maker upbeat
sale key product chromatograph mass spectromet
yoy exclud fx sale key product
yoy sustain growth exclud fx past five year howev sale
grew single-digit manag attribut slow growth
lc market escal competit grow mc market factor specif
shimadzu special generic-rel demand china yoy
neg weak invest drug manufactur japan behind
region mix compar european us rival lower oem sale tof-m
microbi identif system buy restraint ahead introduct new
lc product growth slow yoy quarterli sale mark new
shimadzu see market focu product continu grow stabli
medium term forth lc gs especi ms amid on-going expans
applic field also exist applic develop method use ai
advanc analyt process boost equip replac demand
sentiment support market growth
start shimadzu longer disclos product figur key product
howev ms gc increas ms lc ms increas sale increas
launch new product septemb global demand environment
equip food safeti applic within ms sale maldi tof ms microbi
identif system oem custom decreas sinc
neg overcom achiev yoy growth maldi tof ms microbi identif
system partner biomerieux franc shift antigen-antibodi reaction
method mass spectromet analysi changeov come end
situat expect continu medium-term outlook rebound
demand includ replac demand
gc field new product nexgen gc launch septemb achiev rapid
analysi time compact footprint due use proprietari stainless steel
page
pleas see import disclosur inform page report
column structur system gain penetr among custom sale
brisk
contrast lc sale declin slightli yoy main factor snapback
generic-rel special demand china lower pharmaceut invest japan
lower generic-rel demand india shimadzu announc new lc product march
shimadzu two lc lien high-end model nexera standard model promin
new product promin seri first updat year compar
previou model new product featur compact instal footprint
higher throughput increas data reliabl also brand integr
nexera line
shimadzu see market domest oversea next year unit
plan book sale expect roughli yoy growth
chart chromatograph mass spectromet sale
entri q-tof market
step respons high-
pharmaceut field develop target shift low molecular weight
drug high molecular weight drug along market high-sensit
lcm high-spe analysi lc expand meet need rapid highli
precis analysi molecular weight compound respons taken lead
q-tof product develop agil upgrad product well thermo
fisher introduc orbitrap-typ high-sensit ms field well product
appear one underpin earn growth firm sinc
june shimadzu announc entri q-top tripl quadrupol time
flight mass spectromet market mark compani entri field
product line-up lack high-end mass spectromet market refer
compani note expect ms busi growth issu juli detail
current system user evalu stage given shimadzu latecom
q-tof field manag say compani superior analysi stabil
gain high mark user especi differ thermal condit shimadzu
target first-year sale unit price depend configur standard
page
pleas see import disclosur inform page report
price seem upper ten million yen rang result month
sinc launch appear line annual target target sale unit
guidanc analyt instrument sale yoy op
growth exclud fx partli slower
growth key product howev guidanc growth
bio-medicin develop system
develop system
sophist self-diagnost function improv auto-sampl greater high-volum
analysi reduc
consum /applic upgraded/expand well
new ms product repres upgrad line-up achiev high-spe data
process use ai cultiv new field drug discoveri medicin biolog use
solut after-sal servic
new solut busi unit establish februari integr develop
market softwar product includ network system aim construct
upgraded/fast softwar develop incorpor new technolog
construct new healthcar centr complet februari
centr includ lab collabor research open innov project alreadi
underway includ sophist earli cancer screening/analysi system
kobe univers nation cancer centr develop autom pre-
process system food analysi european contract analysi compani valid
test ip portal next next-gener cell busi plan collabor
page
pleas see import disclosur inform page report
